Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;53(2):141-159.
doi: 10.15586/aei.v53i2.1221. eCollection 2025.

A Delphi consensus on diagnosis, management, and treatment with allergen immunotherapy of polysensitized children in Spain: CAPP study, Part 2

Ana I Tabar  1 , Helena Larramona Cabrera  2 , Cristina Rivas-Juesas  3 , Francisco J Canals Candela  4 , Maria Del Mar Folqué  5 , Miguel Tortajada-Girbés  6 , Ana Martínez-Cañavate  7 , José Manuel Lucas Moreno  8 , María Mesa-Del-Castillo  9
Affiliations

A Delphi consensus on diagnosis, management, and treatment with allergen immunotherapy of polysensitized children in Spain: CAPP study, Part 2

Ana I Tabar et al. Allergol Immunopathol (Madr). .

Abstract

Background: The study aimed to evaluate the level of agreement between specialists in pediatric allergology regarding the diagnosis and indications for allergen immunotherapy (AIT) for dust mites, molds, animal dander, and Hymenoptera venom allergen, as well as mixtures of several allergen sources in polysensitized children in Spain.

Materials and methods: A Delphi study was performed using an online survey designed by a committee of pediatric AIT experts: 46 and 44 panelists participated in Rounds 1 and 2, respectively. In Round 1, 204 statements on 8 dimensions were evaluated (Diagnosis, Therapeutic management, and Pollens - Part I; Mites, molds, animals, hymenoptera venom, and mixtures - Part II). A total of 148 statements were finally accepted after Round 2. Panel members rated their level of agreement with assessments on a 9-point Likert scale based on acceptance by ≥ 66.7 of them.

Results: Panel experts recommended molecular diagnosis for dust mite allergy diagnosis in polysensitized pediatrics and mixtures of nonhomologous mites (Dermatophagoides and Lepidoglyphus) for optimal AIT management. Subcutaneous AIT with mold extracts is recommended, but no agreement was reached on mixing different mold types. Panel experts agreed that Fel d 1 and Can f 1 sIgE are better predictors for animal dander allergy , but no agreement exists on the acceptance of AIT with dander mixtures. Panelists accepted that Api m 2 (hyaluronidase) sIgE indicates Vespid and Apis mellifera cross-reactivity in children; and Api m 4 (melittin) sIgE is a marker of risk for systemic reaction with AIT in Apis mellifera allergy. According to the consensus, SCIT is more suitable for allergen mixtures than SLIT. and agreement was reached for pollen allergens and Alternaria alternata mixtures if stability, safety, and efficacy have been demonstrated.

Conclusions: This Delphi study provides, where evidence is lacking, current expert-based opinions on clinical decision-making for managing polysensitized children.

Keywords: Delphi method; allergen immunotherapy; children; consensus; diagnosis; polysensitization.

PubMed Disclaimer

Conflict of interest statement

A.I.T. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Diater, Inmunotek, InnoUp, ITAI, Leti Pharma, Probelte and Roxall. C.R.-J. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Diater, Leti Pharma, Merck and Novartis; and has received payment for expert testimony from ALK. F.J.C.C. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Allergopharma, Diater, Leti Pharma, and Stallergenes. A.M.-C. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Diater, Inmunotek, Leti Pharma, and Roxall. M.M. del C. has received payment or honoraria as speaker in educational events from Diater and Leti Pharma. H.L.C., M.M.F., M.T.-G., A.M.-T., and J.M.L.M. declare no conflict of interest.

References

    1. 1. Demoly P, Passalacqua G, Pfaar O, Sastre J, Wahn U. Management of the polyallergic patient with allergy immunotherapy: A practice-based approach. Allergy Asthma Clin Immunol. 2016;12:2. 10.1186/s13223-015-0109-6 - DOI
    1. 2. Arbes SJ, Jr., Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116(2):377–83. 10.1016/j.jaci.2005.05.017 - DOI
    1. 3. Bousquet PJ, Castelli C, Daures JP, Heinrich J, Hooper R, Sunyer J, et al. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann Epidemiol. 2010;20(11):797–803. 10.1016/j.annepidem.2010.05.012 - DOI
    1. 4. Vidal C, Enrique E, Gonzalo A, Moreno C, Tabar AI. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: An allergist’s consensus. Clin Transl Allergy. 2014;4:36. 10.1186/2045-7022-4-36 - DOI
    1. 5. Ojeda P, Sastre J, Olaguibel JM, Chivato T. Alergológica 2015: A national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28(3):151–64. 10.18176/jiaci.0264 - DOI

LinkOut - more resources